Advances in the pathogenesis of autoimmune hepatitis and new targets for clinical intervention

Mingli HU; Qixia WANG; Xiong MA

doi:10.3969/j.issn.1001-5256.2022.04.002

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 743-747

PDF( 1912 KB)

Advances in the pathogenesis of autoimmune hepatitis and new targets for clinical intervention

DOI: 10.3969/j.issn.1001-5256.2022.04.002

Mingli HU,
Qixia WANG^{,
,},
Xiong MA^{,
,}

Shanghai Institute of Digestive Disease, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, China

Research funding:

National Natural Science Foundation of China (82130017);

National Natural Science Foundation of China (82070581);

National Natural Science Foundation of China (81790634);

The Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai (2017YQ037);

Shanghai Rising-Star Program (18QA1402700)

More Information

Corresponding author: WANG Qixia, wqx0221155@126.com(ORCID: 0000-0002-8300-6314); MA Xiong, maxiongmd@163.com(ORCID: 0000-0001-9616-4672)
Received Date: 2021-11-30
Accepted Date: 2022-01-13
Published Date: 2022-04-20

Abstract

Abstract

Autoimmune hepatitis (AIH) is an immune-mediated liver disease with hepatocytes as the main target cells. It is characterized by the high immunoglobulin G level and the presence of autoantibodies, and histological observation shows interface hepatitis at the portal area caused by a large amount of lymphoplasmacytic infiltration. The pathogenesis of AIH has not been fully elucidated. At present, glucocorticoid combined with azathioprine is mainly used as non-specific immunosuppressive therapy, and most patients tend to have good response; however, rebound or relapse is often observed during dose reduction or after drug withdrawal, so most patients need long-term maintenance therapy. This article briefly reviews the advances in the pathogenesis of AIH and the potential new targets for clinical intervention, in order to provide a reference for clinical translational research.
- Hepatitis, Autoimmune,
- Pathologic Processes,
- Therapeutics,
- Targets

FullText(HTML)

References(39)

References

[1]	MIELI-VERGANI G, VERGANI D, CZAJA AJ, et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4: 18017. DOI: 10.1038/nrdp.2018.17.
[2]	TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, VERGANI D. Autoimmmune hepatitis[J]. Cell Mol Immunol, 2021. DOI: 10.1038/s41423-021-00768-8.[Online ahead of print]
[3]	MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
[4]	THAN NN, HODSON J, SCHMIDT-MARTIN D, et al. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group[J]. JHEP Rep, 2019, 1(6): 437-445. DOI: 10.1016/j.jhepr.2019.10.005.
[5]	LIBERAL R, de BOER YS, HENEGHAN MA. Established and novel therapeutic options for autoimmune hepatitis[J]. Lancet Gastroenterol Hepatol, 2021, 6(4): 315-326. DOI: 10.1016/S2468-1253(20)30328-9.
[6]	de BOER YS, van GERVEN NM, ZWIERS A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1[J]. Gastroenterology, 2014, 147(2): 443-452.e5. DOI: 10.1053/j.gastro.2014.04.022.
[7]	OLIVEIRA LC, PORTA G, MARIN ML, et al. Autoimmune hepatitis, HLA and extended haplotypes[J]. Autoimmun Rev, 2011, 10(4): 189-193. DOI: 10.1016/j.autrev.2010.09.024.
[8]	WEBB G, CHEN YY, LI KK, et al. Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease[J]. J Hepatol, 2016, 64(5): 1190-1193. DOI: 10.1016/j.jhep.2016.01.017.
[9]	COOKSON S, CONSTANTINI PK, CLARE M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis[J]. Hepatology, 1999, 30(4): 851-856. DOI: 10.1002/hep.510300412.
[10]	TERZIROLI BERETTA-PICCOLI B, DI BARTOLOMEO C, DELEONARDI G, et al. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents[J]. J Autoimmun, 2019, 102: 89-95. DOI: 10.1016/j.jaut.2019.04.019.
[11]	WEILER-NORMANN C, SCHRAMM C. Drug induced liver injury and its relationship to autoimmune hepatitis[J]. J Hepatol, 2011, 55(4): 747-749. DOI: 10.1016/j.jhep.2011.02.024.
[12]	WEI Y, LI Y, YAN L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3): 569-577. DOI: 10.1136/gutjnl-2018-317836.
[13]	BOVENSIEPEN CS, SCHAKAT M, SEBODE M, et al. TNF-producing Th1 cells are selectively expanded in liver infiltrates of patients with autoimmune hepatitis[J]. J Immunol, 2019, 203(12): 3148-3156. DOI: 10.4049/jimmunol.1900124.
[14]	JARUGA B, HONG F, KIM WH, et al. IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: A critical role of IRF-1[J]. Am J Physiol Gastrointest Liver Physiol, 2004, 287(5): G1044-G1052. DOI: 10.1152/ajpgi.00184.2004.
[15]	LIBERAL R, GRANT CR, HOLDER BS, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway[J]. Hepatology, 2012, 56(2): 677-686. DOI: 10.1002/hep.25682.
[16]	MURATORI L, PAROLA M, RIPALTI A, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane[J]. Gut, 2000, 46(4): 553-561. DOI: 10.1136/gut.46.4.553.
[17]	TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, VERGANI D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview[J]. J Autoimmun, 2018, 95: 144-158. DOI: 10.1016/j.jaut.2018.10.004.
[18]	MA Y, BOGDANOS DP, HUSSAIN MJ, et al. Polyclonal T-cell responses to cytochrome P450ⅡD6 are associated with disease activity in autoimmune hepatitis type 2[J]. Gastroenterology, 2006, 130(3): 868-882. DOI: 10.1053/j.gastro.2005.12.020.
[19]	ZHAO L, TANG Y, YOU Z, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression[J]. PLoS One, 2011, 6(4): e18909. DOI: 10.1371/journal.pone.0018909.
[20]	LIBERAL R, GRANT CR, YUKSEL M, et al. Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis[J]. Hepatology, 2017, 66(5): 1570-1584. DOI: 10.1002/hep.29307.
[21]	GRANT CR, LIBERAL R, HOLDER BS, et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis[J]. Hepatology, 2014, 59(3): 1007-1015. DOI: 10.1002/hep.26583.
[22]	MA L, QIN J, JI H, et al. Tfh and plasma cells are correlated with hypergammaglobulinaemia in patients with autoimmune hepatitis[J]. Liver Int, 2014, 34(3): 405-415. DOI: 10.1111/liv.12245.
[23]	YOU Z, LI Y, WANG Q, et al. The clinical significance of hepatic CD69⁺ CD103⁺ CD8⁺ resident-memory T cells in autoimmune hepatitis[J]. Hepatology, 2021, 74(2): 847-863. DOI: 10.1002/hep.31739.
[24]	BÉLAND K, MARCEAU G, LABARDY A, et al. Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells[J]. Hepatology, 2015, 62(5): 1511-1523. DOI: 10.1002/hep.27991.
[25]	LIU X, JIANG X, LIU R, et al. B cells expressing CD11b effectively inhibit CD4⁺ T-cell responses and ameliorate experimental autoimmune hepatitis in mice[J]. Hepatology, 2015, 62(5): 1563-1575. DOI: 10.1002/hep.28001.
[26]	ERHARDT A, BIBURGER M, PAPADOPOULOS T, et al. IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice[J]. Hepatology, 2007, 45(2): 475-485. DOI: 10.1002/hep.21498.
[27]	LONGHI MS, MA Y, MITRY RR, et al. Effect of CD4⁺ CD25⁺ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis[J]. J Autoimmun, 2005, 25(1): 63-71. DOI: 10.1016/j.jaut.2005.05.001.
[28]	LIBERAL R, GRANT CR, HOLDER BS, et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression[J]. Hepatology, 2015, 62(3): 863-875. DOI: 10.1002/hep.27884.
[29]	JEFFERY HC, BRAITCH MK, BAGNALL C, et al. Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis[J]. Hepatol Commun, 2018, 2(4): 421-436. DOI: 10.1002/hep4.1163.
[30]	TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J]. J Hepatol, 2014, 61(5): 1106-1114. DOI: 10.1016/j.jhep.2014.05.034.
[31]	ZHANG H, LIAN M, ZHANG J, et al. A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation[J]. Hepatology, 2018, 67(1): 232-246. DOI: 10.1002/hep.29418.
[32]	LIAN M, ZHANG J, ZHAO L, et al. Interleukin-35 regulates immune microenvironment of autoimmune hepatitis through inducing the expansion of myeloid-derived suppressor cells[J]. Front Immunol, 2019, 10: 2577. DOI: 10.3389/fimmu.2019.02577.
[33]	ZHANG H, LIU Y, BIAN Z, et al. The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury[J]. J Autoimmun, 2014, 53: 55-66. DOI: 10.1016/j.jaut.2014.02.010.
[34]	LI B, LIAN M, LI Y, et al. Myeloid-derived suppressive cells deficient in liver X receptor α protected from autoimmune hepatitis[J]. Front Immunol, 2021, 12: 732102. DOI: 10.3389/fimmu.2021.732102.
[35]	ARVANITI P, GIANNOULIS G, GABETA S, et al. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis[J]. JHEP Rep, 2020, 2(4): 100123. DOI: 10.1016/j.jhepr.2020.100123.
[36]	LAPIERRE P, BÉLAND K, YANG R, et al. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance[J]. Hepatology, 2013, 57(1): 217-227. DOI: 10.1002/hep.26023.
[37]	ROSENZWAJG M, LORENZON R, CACOUB P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial[J]. Ann Rheum Dis, 2019, 78(2): 209-217. DOI: 10.1136/annrheumdis-2018-214229.
[38]	WEILER-NORMANN C, SCHRAMM C, QUAAS A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis[J]. J Hepatol, 2013, 58(3): 529-534. DOI: 10.1016/j.jhep.2012.11.010.
[39]	HSU MC, LIU SH, WANG CW, et al. JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis[J]. Eur J Pharmacol, 2017, 812: 113-120. DOI: 10.1016/j.ejphar.2017.07.012.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(13)

1.	王婧婧，张瑜，韩振坤. 血清白蛋白/碱性磷酸酶比值对自身免疫性肝炎患者免疫抑制剂治疗效果的预测价值. 新乡医学院学报. 2025(02): 155-159 .
2.	陈晨，李竹蓉，吕思学，郭地，武嘉文，杨娜，刘杨. 低剂量白细胞介素-2对自身免疫性肝炎小鼠的肝保护作用及其机制. 解放军医学杂志. 2025(02): 214-220 .
3.	侯艺文，刘莹，李竹蓉，陈晨，李振城，刘杨. 环状RNA参与自身免疫性肝炎小鼠肝损伤的相关性分析. 中国组织工程研究. 2024(14): 2152-2158 .
4.	李娟，哈小琴，卢利霞. 自身免疫性肝病发病机制的研究进展. 实用临床医药杂志. 2024(17): 137-142 .
5.	陶飞宝，施维群. 基于数据挖掘分析中医药治疗自身免疫性肝病组方用药规律. 新中医. 2024(19): 13-18 .
6.	李晓宁，田敏，林婷，荆华，邢斌瑜，申存毅，张惠林，苏娟. 基于胆红素、国际标准化比率探讨自身免疫性肝炎肝移植时机的研究. 湖南师范大学学报(医学版). 2024(03): 110-114+125 .
7.	郝君玉，刘光伟，谢露，范文艳，陈虹秀. 中药有效成分干预自身免疫性肝炎相关信号通路的研究进展. 临床肝胆病杂志. 2023(03): 663-670 . 本站查看
8.	延欢欢，申文文. Th17/Treg比值、LECT2、CXCL10与自身免疫性肝炎患者肝功能和治疗后应答的关系研究. 检验医学与临床. 2023(09): 1226-1230 .
9.	赵娟，徐斌. 进修医师自身免疫性肝炎临床带教体会. 继续医学教育. 2023(06): 129-132 .
10.	彭世秀，李春燕，黄爱萍，朱松涛，麦静，伍丽萍. HIV感染合并自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征1例报告. 临床肝胆病杂志. 2023(09): 2175-2178 . 本站查看
11.	余钰娟，毛德文，刘茵，周晓云. 单味中药治疗自身免疫性肝炎的研究进展. 中国现代医生. 2023(30): 120-122+125 .
12.	郝君玉，陈虹秀，范文艳，刘光伟. 自身免疫性肝炎中医证型与临床特点的多中心回顾性研究. 现代中西医结合杂志. 2023(16): 2228-2232+2240 .
13.	叶雯，徐建良，杨妮. 微RNA在自身免疫性肝炎中的研究进展. 中国医药导报. 2023(28): 58-61 .

Other cited types(5)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1375) PDF downloads(310)

Advances in the pathogenesis of autoimmune hepatitis and new targets for clinical intervention

DOI: 10.3969/j.issn.1001-5256.2022.04.002